Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider
Yoji Sato(National Institute of Health Sciences), Jan Willem van der Laan(Medicines Evaluation Board), Genevíève Gowing(Cedars-Sinai Medical Center), Hideaki Bando(Aichi Cancer Center), Carla Herberts(Medicines Evaluation Board), Lucilia Pereira Mouriès(Health and Environmental Sciences Institute), William Shingleton, B. Surmacz-Cordle(Cell and Gene Therapy Catapult), Timothy K. MacLachlan(Novartis (United States)), Shawna M Jackman(Charles River Laboratories (United States)), Michaela Sharpe(University of Oxford), Kōichi Yamamoto(Osaka City General Hospital), Giulia Leoni(Cell and Gene Therapy Catapult), James W. McBlane, Matteo Piazza(Boehringer Ingelheim (United States)), Silvana Libertini(Novartis (Switzerland))
Cited by 166
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease
|Neuron|2006|1.3k
Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the Brain
|Journal of Neuroscience|2007|874
Risk factors in the development of stem cell therapy
|Journal of Translational Medicine|2011|760
TRPC3 and TRPC6 are essential for angiotensin II‐induced cardiac hypertrophy
|The EMBO Journal|2006|417